Idiopathic Capillary Leak Syndrome (ICLS)

Idiopathic capillary leak syndrome is a very rare condition where tiny blood vessels (capillaries) suddenly become “leaky.” During an attack, fluid and proteins move out of the bloodstream into the surrounding tissues. Because fluid leaves the blood, the blood pressure falls, the blood gets unusually concentrated (high hematocrit), and blood protein levels drop (low albumin). Doctors often describe this typical triad as hypotension, hemoconcentration, and hypoalbuminemia when no other clear cause of shock is present. These episodes usually come in phases: a short prodrome (nonspecific symptoms), a leak phase (shock and swelling), and a recovery phase (fluid returns to the bloodstream and can overload the heart and lungs). Without quick care, attacks can be life-threatening. Many adults with idiopathic capillary leak syndrome also have a small, stable abnormal blood protein called a monoclonal gammopathy (MGUS); it is an association, not a proven cause. ASH Publications+4American College of Physicians Journals+4PMC+4

Idiopathic Systemic Capillary Leak Syndrome (ISCLS) is a rare condition in which the tiny blood vessels (capillaries) suddenly become very “leaky,” so fluid and proteins rapidly leave the bloodstream and move into tissues. This causes a classic triad at the time of an attack: low blood pressure (shock), thickened blood with a very high hematocrit (hemoconcentration), and low blood protein/albumin (hypoalbuminemia). Attacks begin over hours, can be life-threatening, and often recur. Because the signs overlap with sepsis, ISCLS is frequently misdiagnosed; recognizing the triad is critical. PMC+2American College of Physicians Journals+2

---

Other names

Doctors and articles may call this condition by several names. Knowing them helps when reading reports:

• Clarkson disease or Clarkson’s disease — named after the physician who first described it in 1960. PubMed

• Systemic capillary leak syndrome (SCLS) — the broad clinical name. Orpha

• Idiopathic systemic capillary leak syndrome (ISCLS) — emphasizes that no secondary cause is found. PMC

• Primary capillary leak syndrome — used to distinguish it from “secondary” forms caused by other diseases or drugs. ScienceDirect

---

Types

Although all cases share the same core features, clinicians often describe ICLS using these practical groupings:

1. Primary (idiopathic) SCLS vs secondary capillary leak
   “Primary/idiopathic” means no other cause is found. “Secondary” refers to capillary leak from another cause (e.g., severe infection/sepsis, cytokine therapies, certain cancer drugs, engraftment syndrome, or other illnesses). This distinction matters because treatment and prevention differ. ScienceDirect

2. MGUS-associated vs non-MGUS
   Most adults with idiopathic SCLS have a monoclonal gammopathy (often IgG-κ MGUS). Its role is still being studied, but the association is important for diagnosis and follow-up. ASH Publications+1

3. By attack phase

   • Prodromal phase (1–2 days): nonspecific symptoms like fatigue, myalgias, thirst, and sudden weight gain.

   • Leak (resuscitation) phase: shock, hemoconcentration, hypoalbuminemia, swelling, very low urine output.

   • Recovery (recruitment) phase: fluids shift back into the blood; risk of pulmonary edema and fluid overload if large volumes were given early. Cleveland Clinic+1

4. Adult-onset vs childhood-onset
   Most cases occur in adults, but pediatric cases exist and look similar clinically. Rare Diseases Journal

---

Causes

Strictly speaking, idiopathic means the true cause is unknown. But episodes often follow triggers, and many other conditions can mimic SCLS (“secondary capillary leak”). Below are 20 well-described triggers/associations and look-alikes that clinicians consider. This is useful because treatment depends on whether the leak is idiopathic or secondary.

1. Viral respiratory infections (e.g., influenza) — many patients report a viral-like illness before an attack. The immune response can make capillaries leaky. American College of Physicians Journals

2. Other viral infections (including SARS-CoV-2) — infections can precede or precipitate attacks through cytokine surges and endothelial injury. New England Journal of Medicine

3. Bacterial infections — sometimes precede idiopathic attacks; they also cause sepsis, a separate common cause of secondary capillary leak that must be excluded. ScienceDirect

4. Strenuous exercise — reported as a temporal trigger in some adults; likely via transient inflammatory and endothelial changes. American College of Physicians Journals

5. Recent vaccinations — rare pharmacovigilance signals link vaccines to capillary leak events; temporal association does not prove causation, but clinicians remain alert. PMC

6. Monoclonal gammopathy (MGUS) association — not a proven cause, but present in most adult idiopathic cases and may relate to endothelial dysfunction. ASH Publications

7. Dehydration preceding illness — can amplify hemoconcentration and apparent severity when the leak begins. (Clinical inference consistent with triad and management guidance.) American College of Physicians Journals

8. Allergic-type prodrome — some patients note rash or flu-like symptoms before attacks, reflecting immune activation. American College of Physicians Journals

9. Sepsis (secondary cause to exclude) — the most common cause of capillary leak overall; if present, the case is secondary, not idiopathic. Cleveland Clinic

10. Cytokine therapies (e.g., high-dose interleukin-2) — well-known cause of secondary capillary leak during cancer or immunotherapy. ScienceDirect

11. Certain monoclonal antibody drugs — some biologics can produce secondary capillary leak syndromes. ScienceDirect

12. Gemcitabine and other chemotherapies — reported to cause secondary capillary leak; must be recognized in treated cancer patients. ScienceDirect

13. Engraftment syndrome after stem-cell transplant — causes diffuse capillary leak; different mechanism and management from idiopathic SCLS. ScienceDirect

14. Ovarian hyperstimulation syndrome — another medical condition with severe systemic capillary leak; must be distinguished from idiopathic SCLS. ScienceDirect

15. Severe burns/trauma — produce massive secondary vascular leak; part of the differential diagnosis. ScienceDirect

16. Acute pancreatitis — systemic inflammatory response can drive capillary leak; again, a secondary form. ScienceDirect

17. Snake or insect envenomation — toxins can damage endothelium and cause capillary leak; a secondary cause. ScienceDirect

18. Toxic shock syndromes — profound cytokine release causes capillary leak; must be ruled out. ScienceDirect

19. Anaphylaxis — severe allergic reactions can produce acute hypotension and edema via vascular leak; part of the differential. American College of Physicians Journals

20. Cardiogenic/shock states (to exclude) — heart failure and cardiogenic shock can mimic fluid shifts; echocardiography helps separate these from idiopathic SCLS. American College of Physicians Journals

---

Symptoms

1. Sudden fatigue — many people feel unusually tired 1–2 days before an attack. This is part of the prodrome. Cleveland Clinic

2. Muscle aches — body or muscle pain is common early. It feels like a flu. Osmosis

3. Increased thirst — people often drink more because fluid is shifting out of the bloodstream. Cleveland Clinic

4. Sudden weight gain — the body holds fluid in tissues, so the scale may jump before swelling is obvious. Cleveland Clinic

5. Lightheadedness or dizziness — blood pressure drops as fluid leaves the blood vessels. American College of Physicians Journals

6. Fainting or near-fainting — very low blood pressure can cause syncope. American College of Physicians Journals

7. Swelling of arms and legs (edema) — fluid collects in tissues; limbs may feel tight or painful. Orpha

8. Very little urine (oliguria) — kidneys get less blood flow during the leak phase. American College of Physicians Journals

9. Cold, clammy skin — the body shunts blood to vital organs during shock. American College of Physicians Journals

10. Fast heartbeat (tachycardia) — a common response to low blood pressure. American College of Physicians Journals

11. Shortness of breath — can occur in the recovery phase when fluid returns to the blood and backs up into the lungs. Cleveland Clinic

12. Chest discomfort or tightness — from low blood supply or fluid shifts; needs urgent evaluation to rule out other causes. American College of Physicians Journals

13. Abdominal pain or nausea — part of the prodrome or due to poor organ perfusion. Osmosis

14. Confusion — very low blood pressure can reduce blood flow to the brain. American College of Physicians Journals

15. Compartment-type limb pain — tight, painful muscles from swelling in a closed space; rare but serious. SpringerOpen

---

Diagnostic tests

A) Physical-exam bedside checks

1. Blood pressure in both arms, repeated — persistent low pressure with cool, clammy skin points to shock from a leak. In SCLS the low pressure occurs with very concentrated blood and low albumin. American College of Physicians Journals

2. Heart rate and capillary refill — fast pulse and slow refill signal poor circulation during the leak phase. American College of Physicians Journals

3. Weight and limb circumference — sudden weight gain and enlarging limbs suggest fluid moving into tissues. Cleveland Clinic

4. Lung and heart exam — crackles during recovery suggest fluid overload; a quiet chest during the leak phase is common. Cleveland Clinic

5. Focused exam for compartment syndrome — tense, tender compartments with pain on passive stretch require urgent attention. SpringerOpen

B) “Manual” or bedside functional tests

6. Orthostatic vitals — measuring BP and pulse lying/standing can show fragile circulation but must be done carefully in shock. American College of Physicians Journals

7. Strict input–output charting — very low urine output in the leak phase helps gauge severity. American College of Physicians Journals

8. Bedside ultrasound of the neck veins/IVC — a tiny, collapsible IVC suggests low intravascular volume from leakage. American College of Physicians Journals

9. Peripheral pulse oximetry — continuous O₂ monitoring helps detect hypoxemia, especially in the recovery phase with pulmonary edema. American College of Physicians Journals

C) Laboratory and pathology tests

10. Complete blood count (CBC) — shows hemoconcentration (high hematocrit) during an attack. This is a key part of the diagnostic triad. PMC

11. Serum albumin and total protein — low albumin without albumin loss in urine supports SCLS. Another part of the triad. scholarlycommons.gbmc.org

12. Basic metabolic panel — checks kidney function and electrolytes; kidneys may suffer from low perfusion. American College of Physicians Journals

13. Serum lactate — elevated lactate signals tissue hypoperfusion during shock. American College of Physicians Journals

14. Serum/urine protein electrophoresis & immunofixation — looks for MGUS (a monoclonal protein) commonly associated with idiopathic SCLS. ASH Publications

15. Inflammatory markers (CRP/ESR) — may rise with infection or inflammation; help assess triggers but are nonspecific. American College of Physicians Journals

16. Blood cultures & viral testing as indicated — to exclude sepsis and identify infections that could trigger or mimic SCLS. ScienceDirect

17. Urinalysis (including protein) — helps exclude nephrotic-range albumin loss; in ICLS, albumin is low in blood without heavy urinary loss. scholarlycommons.gbmc.org

18. Cardiac biomarkers (BNP/NT-proBNP, troponin) — help differentiate cardiogenic causes and detect strain from fluid shifts. American College of Physicians Journals

D) Electrodiagnostic & monitoring

19. 12-lead ECG — checks for tachycardia, ischemia, or arrhythmias during shock and recovery. It also helps separate heart-related causes. American College of Physicians Journals

20. Continuous cardiac and blood-pressure monitoring — essential during the leak and recovery phases to guide fluids and detect overload early. American College of Physicians Journals

E) Imaging tests

• Echocardiography — rules out heart failure/cardiogenic shock and evaluates filling during resuscitation. American College of Physicians Journals

• Chest X-ray — often clear during the leak phase; may show pulmonary edema during recovery when fluid shifts back into the blood. Cleveland Clinic

• Point-of-care ultrasound (POCUS) of lungs — detects interstitial fluid early in recovery. Cleveland Clinic

• CT chest (when needed) — excludes alternative emergencies (e.g., pulmonary embolism) in the right clinical setting. American College of Physicians Journals

Non-pharmacological treatments (therapies & supportive actions)

1. Immediate recognition of the triad — Train ED/ICU teams to recognize hypotension + hemoconcentration + hypoalbuminemia. Purpose: reduce delays in correct care. Mechanism: pattern recognition triggers appropriate fluid/vasopressor strategy and SCLS-specific precautions. PMC

2. Early ICU admission and continuous monitoring — Admit to an ICU for invasive blood pressure monitoring and frequent labs. Purpose: tighter hemodynamic control. Mechanism: continuous assessment allows rapid titration of fluids and vasopressors during leak and careful diuresis during recovery. PMC

3. Cautious, goal-directed fluids in the leak phase — Use small boluses guided by perfusion and avoid over-resuscitation. Purpose: maintain organ perfusion without swelling tissues further. Mechanism: fluids restore preload but excess worsens edema; frequent reassessment is key. PMC

4. Prefer crystalloids initially; consider albumin selectively — Start with isotonic crystalloids and consider albumin in refractory hypotension with severe hypoalbuminemia. Purpose: stabilize blood pressure while limiting tissue edema. Mechanism: albumin can raise oncotic pressure and transiently pull fluid intravascularly in selected cases. PMC+2U.S. Food and Drug Administration+2

5. Vasopressor support when needed — If fluids alone do not restore perfusion, start vasopressors (e.g., norepinephrine) per standard shock care. Purpose: maintain mean arterial pressure to protect organs. Mechanism: alpha-adrenergic vasoconstriction increases vascular tone. FDA Access Data

6. Serial labs and focused targets — Check hematocrit, albumin, lactate, creatinine, and electrolytes repeatedly. Purpose: detect worsening leak or recovery-phase fluid shift. Mechanism: trends guide fluid/pressors early and diuretics later. PMC

7. Strict intake/output and daily weights — Track all fluids and urine. Purpose: avoid occult fluid overload; plan the recovery-phase diuresis. Mechanism: balances resuscitation with risk of pulmonary edema when fluid shifts back intravascularly. PMC

8. Limb elevation and skin care for massive edema — Elevate edematous limbs and protect skin. Purpose: reduce compartment pressures and skin breakdown. Mechanism: gravity drainage and off-loading minimize tissue injury during peak leak. PMC

9. Early screening for compartment syndrome — Monitor limb pain, tenseness, paresthesia; involve surgery early if pressures rise. Purpose: prevent ischemic muscle/nerve damage. Mechanism: edema increases fascial compartment pressure, threatening perfusion. PMC

10. Avoid diuretics during the active leak — Hold diuretics in the leak phase; consider them in recovery if pulmonary edema develops. Purpose: prevent worsening intravascular depletion early; resolve overload later. Mechanism: timing aligns with physiologic fluid shifts. PMC

11. Empiric infection workup (and source control if needed) — Because SCLS mimics sepsis, obtain cultures and evaluate for infection. Purpose: rule in/out triggers; treat if present. Mechanism: early differentiation guides appropriate antibiotics while SCLS care proceeds. PubMed

12. Early renal support planning — Monitor for acute kidney injury from hypoperfusion; consult nephrology and prepare for RRT if needed. Purpose: protect renal function and correct severe acid-base issues. Mechanism: continuous therapies can gently manage volume/electrolytes in unstable patients. BioMed Central

13. Airway protection & ventilatory support when indicated — If mental status worsens or pulmonary edema develops in recovery, intubate and ventilate per standard indications. Purpose: maintain oxygenation/ventilation. Mechanism: supports gas exchange during dynamic volume shifts. PMC

14. Thrombosis vigilance in recovery — Assess VTE risk and mobilize early as feasible. Purpose: edema and hemoconcentration can increase clot risk. Mechanism: restoration of intravascular volume plus immobility contributes to thrombosis risk. PMC

15. Patient education before discharge — Teach warning signs (limb pain, swelling, dizziness), carry a medical alert card, and have an emergency plan. Purpose: speed re-presentation and correct treatment in future flares. Mechanism: reduces diagnostic delay at future ED visits. PMC

16. Outpatient prophylaxis planning — Discuss long-term prevention (most often monthly IVIG) and/or oral theophylline/β-agonist as advised by specialists. Purpose: reduce relapse frequency and severity. Mechanism: IVIG has shown strong relapse prevention in cohorts; methylxanthine/β2-agonist may stabilize endothelium. PMC+2criteria.blood.gov.au+2

17. Vaccination & infection-avoidance counseling — Review routine vaccines and sick-day plans; coordinate timing with IVIG when relevant. Purpose: lower infection-triggered flares. Mechanism: fewer viral infections may mean fewer SCLS attacks in some patients. PMC

18. Psychological support — Address anxiety and PTSD after ICU care; provide follow-up. Purpose: improve quality of life and adherence to prophylaxis. Mechanism: counseling and support groups help patients manage a rare, relapsing illness. PMC

19. Written ICU recovery plan — Provide written instructions for monitoring, meds, and when to return. Purpose: reduce readmissions from late pulmonary edema in recovery. Mechanism: anticipates the normal “fluid return” phase. PMC

20. Multidisciplinary follow-up (immunology/hematology/critical care) — Coordinate care across specialties, especially if monoclonal gammopathy is present. Purpose: optimize prevention and manage comorbidities. Mechanism: shared care aligns acute and preventive strategies. PMC

---

Drug treatments

Important: No medicine is FDA-approved specifically for ISCLS. Some are used off-label for acute shock or for relapse prevention based on case series. Always individualize in specialist care.

1. Intravenous Immune Globulin (IVIG, e.g., Privigen 10%) — Use: the best-supported preventive therapy; some centers also use IVIG acutely with minimal fluids. How it’s given: preventive regimens commonly 1–2 g/kg monthly (specialist-directed). Mechanism: not fully known; thought to modulate endothelial inflammation and neutralize triggers. Safety: IVIG labels warn about thrombosis, renal dysfunction, and aseptic meningitis; hydrate and infuse at the minimum practicable rate. Regulatory note: IVIG is FDA-approved for PI, ITP, CIDP, not ISCLS (off-label here). U.S. Food and Drug Administration+3PMC+3American College of Physicians Journals+3

2. Norepinephrine (vasopressor) — Use: first-line pressor in distributive/hypovolemic shock when fluids are insufficient. Dose (from label): titrated IV infusion to effect in ICU. Mechanism: α-adrenergic vasoconstriction raises MAP to perfuse organs. Safety: risk of extravasation/tissue injury; central line preferred. FDA Access Data

3. Albumin (Human) 25% — Use: selected cases of severe hypoalbuminemia with refractory hypotension to augment oncotic pressure. Dose: per label and clinician judgment (e.g., small aliquots with close monitoring). Mechanism: increases intravascular oncotic pressure, drawing fluid into vessels. Safety: volume overload if overused, especially in recovery phase. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

4. Theophylline (oral/IV; or aminophylline IV) — Use: relapse prevention (historical) and occasionally adjunctive therapy; serum level monitoring is essential. Dose (label): individualized to serum levels (typical adult maintenance aims ~10–20 µg/mL). Mechanism: phosphodiesterase inhibition and adenosine antagonism may stabilize endothelium. Safety: narrow therapeutic index; nausea, tremor, arrhythmias, seizures with high levels. FDA Access Data

5. Terbutaline (oral β2-agonist) — Use: prevention adjunct in some patients (off-label). Dose (label for pulmonary use): adults often 5 mg orally every ~6 hours (max 15 mg/day). Mechanism: β2-mediated endothelial effects and cAMP increase may reduce permeability. Safety: tachycardia, tremor; not for prolonged tocolysis; follow label cautions. DailyMed+1

6. Crystalloids (e.g., normal saline, balanced solutions) — Use: first resuscitation fluid in leak phase. Dose: small, frequent boluses guided by perfusion. Mechanism/Safety: restores preload; avoid excessive volumes due to impending recovery-phase fluid return. PMC

7. Empiric broad-spectrum antibiotics (when sepsis can’t be excluded) — Use: standard sepsis bundles while SCLS is considered. Mechanism: treat bacterial triggers early if present. Safety: follow each drug’s FDA label; de-escalate once infection is excluded. PubMed

8. Corticosteroids (e.g., methylprednisolone) — Use: sometimes given in the acute phase; evidence is mixed; not definitive. Mechanism: anti-inflammatory effects might blunt cytokine-driven leak. Safety: hyperglycemia, infection risk; clinician-directed. PMC

9. Vasopressin (adjunct pressor) — Use: add-on if norepinephrine alone insufficient. Mechanism: V1 receptor–mediated vasoconstriction. Safety: ischemia with excessive dosing; label-guided ICU use. PMC

10. Epinephrine (pressors/inotropes) — Use: refractory hypotension or anaphylaxis mimic. Mechanism: α/β effects support pressure and cardiac output. Safety: arrhythmias; ICU titration per label. PMC

11. Analgesics/antipyretics — Use: control limb pain and fever in prodrome. Mechanism: symptom relief; does not alter disease course. Safety: follow individual labels (renal/hepatic cautions). PMC

12. Anticoagulation (e.g., LMWH) when indicated for VTE prophylaxis — Use: individualize based on bleeding risk. Mechanism: reduce VTE during immobility/recovery. Safety: follow drug labels for dosing/renal adjustment. PMC

13. Diuretics (loop diuretics) in the recovery phase — Use: treat pulmonary edema/fluid overload as fluid shifts back intravascularly. Mechanism: promote diuresis after capillaries reseal. Safety: avoid during active leak. PMC

14. Electrolyte replacement (e.g., potassium, magnesium) — Use: correct abnormalities from shifting fluids/pressors/diuretics. Mechanism: maintain cardiac and neuromuscular stability. Safety: label-guided dosing. PMC

15. Proton-pump inhibitors for stress ulcer prophylaxis (ICU standard) — Use: reduce GI bleed risk during shock/pressors. Mechanism: gastric acid suppression. Safety: follow labels; reassess necessity daily. PMC

16. Insulin protocols for stress hyperglycemia — Use: maintain reasonable glucose ranges in ICU. Mechanism: avoids glycemic extremes that worsen outcomes. Safety: nurse-driven protocols; avoid hypoglycemia. PMC

17. Antiemetics for nausea (e.g., ondansetron) — Use: improve comfort and oral intake. Mechanism: 5-HT3 blockade. Safety: QT monitoring per label. PMC

18. Acetazolamide (selected cases) — Use: occasionally to assist diuresis/metabolic alkalosis in recovery; specialist-directed. Mechanism: carbonic anhydrase inhibition. Safety: renal function checks; label-guided. PMC

19. Bronchodilators (e.g., inhaled albuterol) if bronchospasm is present — Use: symptomatic relief; unrelated to capillary leak itself. Mechanism: β2-mediated bronchodilation. Safety: tremor/tachycardia. PMC

20. Vaccines (long-term prevention of infection triggers) — Use: routine immunization schedule, timed around IVIG. Mechanism: reduce infections that may precipitate attacks. Safety: standard contraindications; coordinate with specialists. PMC

---

Dietary molecular supplements

There is no high-quality evidence that any dietary supplement prevents or treats ISCLS. Antioxidant strategies such as high-dose vitamin C have not shown a consistent benefit even in related critical-illness syndromes, and routine use is not recommended for SCLS outside trials. Focus instead on balanced nutrition, adequate protein during recovery, and individualized diet for comorbidities. Always discuss supplements with your clinician because of drug–supplement interactions. evidence.nejm.org

(Because there are no proven supplements for ISCLS, listing “10 specific molecules with doses and mechanisms” would be speculative and potentially unsafe. The safest, evidence-based advice is above.) PMC

---

Immunity-booster, regenerative, or stem-cell drugs

There are no validated immunity-boosting, regenerative, or stem-cell medicines for ISCLS. Monthly IVIG is the preventive therapy with the best evidence, and even that is off-label and guided by specialist teams. Claims of “immune boosters” or stem-cell products for SCLS are not supported by peer-reviewed evidence and should be avoided outside a clinical trial. PMC+1

---

Procedures/surgeries

1. Emergent fasciotomy for compartment syndrome — Massive edema can raise compartment pressures; surgical fasciotomy may be limb-saving. Why: restore perfusion and prevent nerve/muscle death. PMC

2. Endotracheal intubation & mechanical ventilation — For respiratory failure or severe pulmonary edema in recovery. Why: protect airway and maintain oxygenation during rapid fluid shifts. PMC

3. Renal replacement therapy catheter placement (CRRT/HD) — For severe AKI or fluid overload unresponsive to diuretics. Why: gently remove fluid/solutes while unstable. BioMed Central

4. Central venous catheter — For vasopressor infusion and hemodynamic monitoring. Why: safe, reliable drug delivery when peripheral access is risky. FDA Access Data

5. Procedural drainage (rare) — If tense effusions compromise organs (e.g., large pleural effusion), procedural drainage may be needed. Why: relieve pressure and improve breathing/hemodynamics. PMC

---

Prevention strategies

1. Monthly IVIG under specialist supervision (most effective). PMC+1

2. Consider theophylline/terbutaline if IVIG is unavailable or not tolerated (specialist-guided). ATS Journals

3. Infection-avoidance & vaccination plans; prompt care for febrile illness. PMC

4. Carry a medical alert card/letter describing ISCLS and the diagnostic triad. PMC

5. Home monitoring during prodrome: weight, edema, dizziness; low threshold to seek care. PMC

6. Medication review to avoid unnecessary dehydration or hypotension during illnesses. PMC

7. Travel planning: know the nearest ICU, carry records and IVIG schedule. PMC

8. Specialist follow-up (immunology/hematology) for MGUS and relapse prevention. PMC

9. Sick-day hydration plan coordinated with your clinicians. PMC

10. Relapse diary to track triggers and timing. PMC

---

When to see a doctor (or go to the ED)

Seek emergency care immediately for new dizziness, fainting, severe limb pain/swelling, or suddenly worse edema—especially with known SCLS. Go to the ED for fever plus swelling, any chest tightness or shortness of breath, dark low-volume urine, or rapid weight gain in recovery. Arrange urgent clinic follow-up after any hospitalized flare to set prevention (often IVIG). PMC

---

What to eat and what to avoid

During recovery, aim for balanced meals with adequate protein to rebuild albumin and support healing; maintain steady fluids as advised by your team. Avoid alcohol excess and very salty ultra-processed foods if fluid overload is an issue. Do not start “detox” or high-dose supplement regimens: they have no proven benefit and can interact with medicines used in SCLS. PMC+1

---

FAQs

1) Is ISCLS the same as sepsis?
No. ISCLS mimics sepsis but is defined by recurrent episodes of hypotension with hemoconcentration and hypoalbuminemia without infection; clinicians still check for infection because it can trigger or resemble SCLS. PMC+1

2) How rare is it?
It is very rare; most information comes from case reports, registries, and expert reviews. PMC

3) What causes the leak?
Likely transient endothelial barrier dysfunction with inflammatory mediators; exact mechanisms are still being studied. PubMed

4) What is the best prevention?
Monthly IVIG has the strongest evidence for preventing relapses and decreasing severity. PMC+1

5) Do theophylline or terbutaline help?
They have been used (often historically or when IVIG is not available) as prophylaxis; evidence is less robust than IVIG and requires careful monitoring. ATS Journals

6) What happens during the recovery phase?
Fluid that leaked into tissues returns to the bloodstream, so lungs can fill with fluid; clinicians often switch from gentle fluids to careful diuresis. PMC

7) Are there blood tests that prove ISCLS?
There is no single specific test; the diagnosis is clinical (shock + hemoconcentration + hypoalbuminemia) with exclusion of other causes, and often MGUS is present. PMC

8) Can children get ISCLS?
Yes, but most cases are in adults; pediatric cases are reported. Management principles are similar, adapted for age. PMC

9) Is there a cure?
No cure yet. Prevention (usually IVIG) and rapid management of flares are the cornerstones. PMC

10) Why do some people need pressors?
Because vascular leak causes severe hypotension that fluids alone may not correct; norepinephrine helps maintain organ perfusion. FDA Access Data

11) Do steroids work?
They are sometimes tried acutely, but evidence is mixed; they are not a proven preventive therapy. PMC

12) Can I take supplements to prevent attacks?
There is no proven supplement for ISCLS; high-dose vitamin C and similar approaches have not shown consistent benefit in related critical illnesses. evidence.nejm.org

13) What complications should I know about?
Acute kidney injury, compartment syndrome, pulmonary edema during recovery, and thrombosis can occur; close ICU monitoring reduces risks. PMC

14) What should I bring to the hospital?
A card or letter stating you have ISCLS, your typical lab pattern, your prevention regimen (e.g., IVIG schedule), and emergency contacts. PMC

15) Where can my clinicians read more?
Peer-reviewed reviews and case series summarize recognition and management, including Druey et al. (Ann Intern Med/ACP), Xie et al. (IVIG prophylaxis), and recent case discussions of acute IVIG use with minimal fluids. American College of Physicians Journals+3PMC+3American College of Physicians Journals+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 10, 2025.